An association of importers of unregistered medicines has criticised the transitional rules in the draft 2027 budget of the National Health Insurance Fund (NHIF). In a statement, it says the rules will not bring "consolidation" or save money. It says they will add red tape and raise doubts over the treatment of patients with rare diseases.
The NHIF supervisory board approved the draft budget last Tuesday, 10 November, and the health insurance contribution stays at 8%. A week later, on Tuesday 17 November, parliament's budget committee backed the bill at first reading. The association's statement came after that.
The NHIF supervisory board approved the draft 2027 budget on Tuesday 10 November, with one abstention. The total budget is close to 5.68bn euros.
Under the changes, about 45m euros for rare disease drugs will move from the health ministry's budget to the NHIF's. That is less than 1% of the fund's budget.
The association says the transfer does not cut a single office or procedure. The scheme already works this way: since the Fund for Treatment of Children closed, the NHIF approves and pays, and the ministry sends it a targeted transfer. Only the source of the money changes, along with the level at which the legal limits are set.
The ministry's programme "Providing medical care to specific groups of the population" is worth 116.2m euros, of which 110.7m euros is administered spending. The importers say the structure and capacity are already in place, and only the rare disease drugs are taken out of the programme. They say this shifts a state obligation onto health contributions, and the cap that was set never covered it.
The association says the changes are going through without debate and that the payer, the NHIF, will write the rules itself. Without a clear test, it says, there will be "arbitrariness by the payer" instead of price control. It says that refusing to pay for a therapy with no alternative is in practice a refusal of treatment.